



# Nirman Agri Genetics Limited

3rd floor, Samarth House, Opposite Titan World, Mahatma Nagar, Nashik, India, 422005

Email: [cs@nirmanagrigen.com](mailto:cs@nirmanagrigen.com) | Web: [www.nirmanagrigen.com](http://www.nirmanagrigen.com)

CIN No: L01110MH2020PLC344089

**Date: November 14<sup>th</sup>, 2025**

To,  
NSE Limited,  
Department of Corporate Affairs,  
Exchange Plaza, Plot no. C/1, G Block,  
Bandra Kurla Complex, Bandra (E),  
Mumbai-400051,  
Maharashtra, India

**Reference: ISIN: INE0OK701014; Symbol: NIRMAN**

**Subject: Outcome of meeting of the Board of Directors held on Friday, 14<sup>th</sup> November 2025.**

**Dear Sir/Ma'am,**

Pursuant to Regulation 33 and Regulation 30 read with Para A of Part A of Schedule III of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform that the Board of Directors of the Company at its meeting held on Friday, November 14, 2025 has, inter alia, approved:

1. Un-audited Financial Results for the Quarter and Half Year ended September 30, 2025 along with Limited review report ("Financial Results").
2. The Board of directors is of the view that company can not proceed with the any of the corporate actions at this stage. The Company therefore requests NSE to kindly take note of the following:
  - The application for bonus shares submitted by the Company via NEAPS is hereby withdrawn and should not proceed further until such time as SEBI lifts or modifies the interim restrictions.
  - The Company will update and intimate the Exchange and investors when and if the Company is permitted by SEBI to recommence the proposed corporate action or submit a fresh application.
  - The Company confirms that no further corporate action in respect of bonus / split / name change will be effected by the Company until SEBI's further instruction or clearance.
3. The Board of directors of the company has taken note of the Cautionary Email received from your office concerning the delay in submission of intimation regarding the resignation of the Company Secretary & Compliance Officer of the Company, as per Regulation 30 read with sub-para 7 of Para A, Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.



# Nirman Agri Genetics Limited

3rd floor, Samarth House, Opposite Titan World, Mahatma Nagar, Nashik, India, 422005

Email: [cs@nirmanagrigen.com](mailto:cs@nirmanagrigen.com) | Web: [www.nirmanagrigen.com](http://www.nirmanagrigen.com)

CIN No: L01110MH2020PLC344089

- The board also acknowledges the lapse and assures that appropriate internal measures have been put in place to strengthen the compliance mechanism and to ensure that such delays do not recur in the future.
4. The Board noted the resignation of Mr. Avinash Bhimrao Bagal (DIN: 09807701) from the post of Non-executive independent Director with effect from 14th November, 2025, due to his pre-occupation and personal commitments.

In terms of Regulations 30, 33 and 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing a copy of the said Un-Audited Half yearly Financial Results along with a copy of Limited Review Report issued by the Statutory Auditors of the Company.

The meeting of Board of Directors commenced at 5.00 P.M. and concluded at 5:30 P.M

The said notice may be accessed on the website of Stock Exchanges i.e. [www.nseindia.com](http://www.nseindia.com) .

You are requested to take the same into your records and acknowledge.

**Thanking you,**

**Yours faithfully,**

**For Nirman Agri Genetics Limited**

**Pranav**  
**Kailas Bagal**

Digitally signed by  
Pranav Kailas Bagal  
Date: 2025.11.14  
17:41:04 +05'30'

**Pranav Kailas Bagal**  
**Managing Director**  
**DIN: 08839908**



To  
The Board of Directors  
**Nirman Agri Genetics Limited**

## Report on the audit of the Standalone Financial Results

### Opinion

We have audited the accompanying statement of half yearly standalone financial results of **Nirman Agri Genetics Limited** (the “Company”) for the half year ended September, 30th 2025 (“Statement”), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the “Listing Regulations”).

In our opinion and to the best of our information and according to the explanations given to us, the Statement:

- i. is presented in accordance with the requirements of the Listing Regulations in this regard;  
And
- ii. gives a true and fair view in conformity with the applicable accounting standards and other accounting principles generally accepted in India, of the **Net Profit** and other financial information of the Company for the half year ended September 30<sup>th</sup>, 2025.

### Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013, as amended (“the Act”). Our responsibilities under those Standards are further described in the “Auditor’s Responsibilities for the Audit of the Standalone Financial Results” section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our opinion.

### Management’s Responsibilities for the Standalone Financial Results

The Statement has been prepared on the basis of the standalone annual financial statements. The Board of Directors of the Company are responsible for the preparation and presentation of the Statement that gives a true and fair view of the net profit and other financial information in accordance with the applicable accounting standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the



Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the Statement, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.

## **Auditor's Responsibilities for the Audit of the Standalone Financial Results**

Our objectives are to obtain reasonable assurance about whether the Statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the Statement.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represents the underlying transactions and events in a manner that achieves fair presentation.



# M/S. DEVENDRA C. BELAN AND ASSOCIATES

---

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

## **Other Matter**

The Statement includes the results for the half year ended September 30<sup>th</sup> 2025 being the balancing figure between the audited figures in respect of the full financial year ended March 31, 2025 and the unaudited year-to-date figures up to the half of the current financial year, which were subjected to a limited review by us as required under the listing regulations.

For M/s Devendra C. Belan & Associates

Chartered Accountants

Firm Registration No-126495W

Devendra  
Chandrakant  
Belan

Digitally signed by  
Devendra Chandrakant  
Belan  
Date: 2025.11.14 16:20:04  
+05'30'

CA Devendra C. Belan

Proprietor

Membership No. 119372

Place: Nashik

Date: 14/11/2025

UDIN: 25119372BMHTMD3447

**NIRMAN AGRI GENETICS LIMITED**  
**(Formerly known as Nirman Agri Genetics Private Limited)**  
Registered Office Address - 3rd Floor, Samarth House, Opp. Titan World, Mahatma Nagar, Nashik 422005  
CIN - U01110MH2020PLC344089  
**Unaudited Standalone Financial Results for the Half year ended 30th September, 2025**

(Rs. In Lakh )

Particulars		Half year Ended			Year Ended	
		30-09-2025	31-03-2025	30-09-2024	31-03-2025	31-03-2024
Whether results are audited or unaudited		Unaudited	Audited	Unaudited	Audited	Audited
I	Revenue From Operations	14,622.88	12,407.18	11,244.58	23,651.76	6,333.72
II	Other Income	-	-	-	18.44	-
						-
III	<b>Total Income (I+II)</b>	14,622.88	12,407.18	11,244.58	23,670.20	6,333.72
IV	<b>Expenses</b>					
	Cost of Materials Consumed , Cost of Production	12,900.34	10,676.87	9,839.85	20,516.72	4,933.60
	Purchases of Stock -In-Trade	-	-	-	-	-
	Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	-	-	-	-	-
	Employee Benefit Expenses	76.71	91.86	85.78	177.64	147.75
	Finance Costs	-	1.04	1.15	2.19	2.03
	Depreciation and Amortization Expenses	22.78	50.89	12.93	63.82	31.65
	Other Expenses	119.83	185.74	116.65	302.39	124.92
	<b>Total Expenses</b>	13,119.65	11,006.39	10,056.37	21,062.76	5,239.95
V	Profit Before Exceptional and Extraordinary Items and Tax (III-IV)	1,503.23	1,400.79	1,188.21	2,607.44	1,093.77
VI	Exceptional Items					-
VII	Profit Before Extraordinary Items and Tax (V - VI)	1,503.23	1,400.79	1,188.21	2,607.44	1,093.77
VIII	Extraordinary Items					-
IX	Profit Before Tax (VII- VIII)	1,503.23	1,400.79	1,188.21	2,607.44	1,093.77
X	Tax Expense:					
	(1) Current Tax	45.33	32.02	43.06	75.08	49.95
	(2) Deferred Tax		3.76		3.76	3.36
XI	<b>Profit / (Loss) For The Period From Continuing Operations (VII-VIII)</b>	1,457.90	1,365.00	1,145.15	2,528.60	1,040.47
XII	<b>Profit / (Loss) For The Period From Discontinuing Operations</b>	-	-	-	-	-
XIII	<b>Tax Expense of Discontinuing Operations</b>	-	-	-	-	-
XIV	<b>Profit / (Loss) For The Period From Discontinuing Operations (After Tax) (XII-XIII)</b>	-	-	-	-	-
XV	<b>Profit (Loss) For The Period (XI+XIV)</b>	1,457.90	1,365.00	1,145.15	2,528.60	1,040.47

<b>XVI</b>	<b>Deatails of paid up Share Capital</b>					
	Paid up Share Capital	800.97	800.97	800.97	800.97	596.08
	Face Value of Equity Share Capital(Per Share) (in Rs.)	10.00	10.00	10.00	10.00	10.00
<b>XVII</b>	<b>Earnings Per Equity Share (EPS)</b>					
	(i) Basic	18.20	17.04	14.30	31.57	17.46
	(ii) Diluted					

**Notes:**

- 1) The above statement of financial results as approved by the Audit Committee have been approved by the Board of Directors at its meeting held on 14th November 2025.
- 2) The statutory auditors have carried out review of the unaudited results of the company for the half year ended 30/09/2025.
- 3) The company has single reportable business segment. Hence, no separate information for segment wise disclosure is given in accordance with the requirements of Accounting Standard(AS)-17 - "Segment Reporting".
- 4) The above unaudited Standalone financial results are in compliance with Accounting Standards (AS) as prescribed under Section 133 of Companies Act, 2013.
- 5) As per MCA Notification dated 16th February, 2015, Companies whose shares are listed as SME exchange as referred in Chapter XB of SEBI (Issue of Capital and Disclosure Requirements) Regulations,2009, are exempted from the compulsory requirement of adoption of IND-AS.
- 6) The company is not having any subsidiary, associate or joint venture, therefore, it has prepared only standalone results.
- 7) Earing Per Share - EPS is calculated on the weighted average of the share capital received by the company. Half yearly EPS is not annualised.
- 8) The company is listed as SME exchange w.e.f. 28th March, 2023
- 9) Statement of Assets and Liabilities as at 31st March, 2025 and as on 30th September, 2025 is enclosed herewith.
- 10) The Statutory Auditors have issued unmodified opinion on the financial statements of the Company for the half year ended 30th September, 2025.
- 11) The figures for the previous year have been recast/restated wherever is necessary to confirm with the current period's classification.

For & on behalf of the Board of Directors  
Nirman Agri Genetics Limited

Pranav  
Kailas Bagal

Digitally signed by  
Pranav Kailas Bagal  
Date: 2025.11.14  
17:36:00 +05'30'

Pranav Kailas Bagal  
Managing Director  
DIN - 08839908

Place - Nashik  
Date - 14th November 2025

**NIRMAN AGRI GENETICS LIMITED**  
(Formerly known as Nirman Agri Genetics Private Limited)  
Registered Office Address - 3rd Floor, Samarth House, Opp. Titan World, Mahatma Nagar, Nashik 422005  
CIN -U01110MH2020PLC344089  
**Unaudited Statement of Standalone Assets and Liabilities**

(Rs in Lakhs)

	Particulars	Hal Year Ended	Year Ended
		30th September 2025	31st March 2025
		(Unaudited)	(Audited)
<b>I</b>	<b>ASSETS</b>		
<b>1</b>	<b>Non-Current Assets</b>		
(a)	Property, Plant and Equipment and Intangible Assets	194.28	216.87
	(i) Property, Plant and Equipment		
	(ii) Other Intangible Assets		
	(iii) Capital Work-in-Progress		
	(iv) Intangible Assets Under Development		
(b)	Non-Current Investments	1.75	1.75
(c)	Deferred Tax Asset (Net)	-6.76	-6.76
(d)	Long Term Loans and Advances	927.63	1,032.89
(e)	Other Non-Current Assets	17.57	17.57
	<b>Sub-Total</b>	<b>1,134.47</b>	<b>1,262.32</b>
<b>2</b>	<b>Current assets</b>		
(a)	Current Investments		-
(b)	Inventories	3526.16	3,704.81
(c)	Trade Receivables	7866.81	3,750.15
(d)	Cash and Cash Equivalents	134.54	2,587.17
(e)	Short Term Loans and Advances	0.00	-
(f)	Other Current Assets	10.10	3.23
	<b>Sub-Total</b>	<b>11,537.60</b>	<b>10,045.35</b>
	<b>TOTAL ASSETS</b>	<b>12672.07</b>	<b>11307.67</b>
<b>II</b>	<b>EQUITY AND LIABILITIES</b>		
<b>1</b>	<b>Shareholders' Funds</b>		
(a)	Share Capital	800.97	800.97
(b)	Reserves and Surplus	11656.08	10,193.18
(c)	Money Received Against Share Warrants		
	<b>Sub-Total</b>	<b>12,457.05</b>	<b>10,994.15</b>
<b>2</b>	<b>Share Application Money Pending Allotment</b>	-	-
<b>3</b>	<b>Non-Current Liabilities</b>		
(a)	Long-Term Borrowings	0.00	0.00
(b)	Deferred Tax Liabilities (Net)	0.00	0.00
(c)	Other Long Term Liabilities	0.00	0.00
(d)	Long Term Provisions	0.00	0.00
	<b>Sub-Total</b>	<b>0.00</b>	<b>0.00</b>
<b>4</b>	<b>Current Liabilities</b>		
(a)	Short Term Borrowings	34.20	43.87
(b)	Trade Payables	20.43	33.66
	-due from micro and small medium enterprises		
	-due from other than micro and small medium enterprises		
(c)	Other Current Liabilities		0.00
(d)	Short Term Provisions	160.39	236.00
	<b>Sub-Total</b>	<b>215.02</b>	<b>313.52</b>
	<b>TOTAL LIABILITIES</b>	<b>12,672.07</b>	<b>11,307.67</b>

For & on behalf of the Board of Directors  
Nirman Agri Genetics Limited

Pranav  
Kailas Bagal

Digitally signed by  
Pranav Kailas Bagal  
Date: 2025.11.14  
17:36:55 +05'30'

Place - Nashik  
Date - 14th November 2025

Pranav Kailas Bagal  
Managing Director  
DIN - 08839908



**NIRMAN AGRI GENETICS LIMITED**  
**(Formerly known as Nirman Agri Genetics Private Limited)**  
Registered Office Address - 3rd Floor, Samarth House, Opp. Titan World, Mahatma Nagar, Nashik 422005  
CIN -U01110MH2020PLC344089  
**Unaudited Statement of Standalone Cashflow for the hal year ended 30th September 2025**

(Rs in Lakhs)

Particulars	Hal Year Ended	Year Ended
	30th September 2025	31st March 2025
	(Unaudited)	(Audited)
<b>(A) Cash Flows from Operating Activities</b>		
Profit Before Tax	1,503.23	2,607.44
Adjustments for:		
Depreciation and Amortization Expenses	22.78	63.82
Finance Costs	-	2.19
<b>Operating Profit Before Working Capital Changes</b>	<b>1,526.01</b>	<b>2,673.45</b>
<b>Changes In Working Capital</b>		
Increase/(Decrease) in Trade Payables	(13.23)	(499.33)
Increase/(Decrease) in Short Term Borrowings	(9.67)	(0.20)
Increase/(Decrease) in Short Term Provisions	(75.60)	143.31
(Increase)/Decrease in Inventories	178.65	(2,877.09)
(Increase)/Decrease in Trade Receivables	(4,116.67)	(2,591.35)
(Increase)/Decrease in Other Current Assets	(6.87)	14.40
<b>Cash Generated From Operations</b>	<b>(2,517.38)</b>	<b>(3,136.80)</b>
Direct Taxes paid		-
<b>Net Cash Flows from Operating Activities (A)</b>	<b>(2,517.38)</b>	<b>(3,136.80)</b>
<b>(B) Cash Flows From Investing Activities</b>		
Purchase of Fixed Assets(Net)	(0.18)	(241.35)
(Increase)/Decrease in Current Investment	-	-
(Increase)/Decrease in Other Non Current Assets	-	(5.04)
(Increase)/Decrease in Long Term Loans & Advances	105.26	1,178.99
(Increase)/Decrease in DTA	-	3.76
<b>Net Cash Flows from Investing Activities (B)</b>	<b>105.08</b>	<b>936.35</b>
<b>(C) Cash Flows From Financing Activities</b>		
Finance Costs	-	(2.19)
Increase/(Decrease) in Share Capital	-	204.89
Increase/(Decrease) in Share Premium	-	4,691.93
Increase/(Decrease) in Dividend	-	(160.19)
Repayment of Long Term Borrowings		(18.50)
Increase/(Decrease) in Reserves	(40.33)	(83.84)
Repayment of Long Term Provisions		
<b>Net Cash Flows from Financing Activities (C)</b>	<b>(40.33)</b>	<b>4,632.09</b>
<b>Net Increase/(Decrease) in Cash &amp; Cash Equivalents (A+B+C)</b>	<b>(2,452.63)</b>	<b>2,431.64</b>
<b>Cash &amp; Cash Equivalents at the beginning of the year</b>	<b>2587.17</b>	<b>155.53</b>
<b>Cash &amp; Cash Equivalents at the end of the year</b>	<b>134.54</b>	<b>2,587.17</b>

For & on behalf of the Board of Directors  
Nirman Agri Genetics Limited

Pranav  
Kailas Bagal

Digitally signed by  
Pranav Kailas Bagal  
Date: 2025.11.14  
17:37:18 +05'30'

Place - Nashik  
Date - 14th November 2025

Pranav Kailas Bagal  
Managing Director  
DIN - 08839908

## Resignation Letter

**Date: 14/11/2025**

**To,**

The Board of Directors,

**NIRMAN AGRI GENETICS LIMITED**

3rd floor, Samarth House, H P T College, Nashik, Nashik, Maharashtra, India, 422005

**Sub: Resignation from the position of Non Executive Independent Director of the company.**

**Dear Sir/Madam,**

I, Mr. Avinash Bhimrao Bagal (DIN:09807701) Resident of Dhule, Maharashtra, due to pre-occupation and personal commitments ,I hereby tender my resignation from the position of Non Executive Independent Director of the Company with immediate effect. Kindly accept this letter as my resignation with immediate effect from 14<sup>TH</sup> November 2025, from the post of Non Executive Independent Director Of Nirman Agri Genetics Limited and relieve me of my duties.

Kindly acknowledge the receipt of this resignation letter and arrange to submit the necessary forms with the office of the Registrar of Companies, to that effect.

Thanking You,

Yours sincerely,



**Avinash Bhimrao Bagal**

**DIN No.: 09807701**

**Dated: 14/11/2025**